dr-0201
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2023 (NCT06008652)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Dermatomyositis · Phase 1
- Emphysema · Phase 1
- Healthy Volunteers · Phase 1
- Hodgkin Disease · Phase 1
- Lupus Erythematosus, Cutaneous · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lupus Nephritis · Phase 1
- Polymyositis · Phase 1
- Scleroderma, Diffuse · Phase 1
- Scleroderma, Systemic · Phase 1
- Sclerosis · Phase 1
- Sjogren's Syndrome · Phase 1
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06647069 | Phase 1 | Nov 30, 2024 | Dren Bio |
| NCT06392477 | Phase 1 | Jul 15, 2024 | Dren Bio, Novotech |
| NCT06008652 | Phase 1 | Nov 26, 2023 | Dren Bio, Novotech |
Showing 3 of 3 trials
Page 1 / 1